Literature DB >> 21612475

Expanding treatment options for metastatic prostate cancer.

Emmanuel S Antonarakis, Mario A Eisenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21612475      PMCID： PMC3458507          DOI： 10.1056/NEJMe1102758

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Authors:  I F Tannock; D Osoba; M R Stockler; D S Ernst; A J Neville; M J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 7.  Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

Authors:  Karen E Knudsen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

8.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

Authors:  Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

9.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:  Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Maxwell V Meng; Shilpa S Mehta; Peter R Carroll
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
  10 in total
  43 in total

Review 1.  Novel options for the treatment of castration-resistant prostate cancer.

Authors:  Carsten-H Ohlmann; Axel S Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J Mathers; Patrick J Bastian
Journal:  World J Urol       Date:  2011-11-20       Impact factor: 4.226

2.  Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.

Authors:  Dhwanishiva Vasani; David Y Josephson; Courtney Carmichael; Oliver Sartor; Sumanta Kumar Pal
Journal:  Maturitas       Date:  2011-08-09       Impact factor: 4.342

Review 3.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

4.  Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.

Authors:  Scott T Tagawa; Himisha Beltran
Journal:  Asian J Androl       Date:  2011-08-22       Impact factor: 3.285

5.  Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

Authors:  Emmanuel S Antonarakis
Journal:  Asian J Androl       Date:  2011-07-11       Impact factor: 3.285

6.  Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.

Authors:  Tamara Goldberg; Evangelina Berrios-Colon
Journal:  P T       Date:  2013-01

7.  Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.

Authors:  Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

8.  Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells.

Authors:  Hao Xu; Shangjun Wu; Xin Shen; Ding Wu; Zhenguo Qin; Hao Wang; Xiaogang Chen; Xiaoqing Sun
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

9.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Elisabeth I Heath; Edwin M Posadas; Evan Y Yu; Michael R Harrison; Justine Y Bruce; Steve Y Cho; Gregory E Wilding; Gerald J Fetterly; David G Hangauer; Min-Fun R Kwan; Lyn M Dyster; Michael A Carducci
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-13       Impact factor: 3.333

10.  Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Elisabeth I Heath; David C Smith; Dana Rathkopf; Amanda L Blackford; Daniel C Danila; Serina King; Anja Frost; A Seun Ajiboye; Ming Zhao; Janet Mendonca; Sushant K Kachhap; Michelle A Rudek; Michael A Carducci
Journal:  Oncologist       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.